Ryan J Sullivan Selected Research

ulixertinib

1/2018	First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.
1/2018	Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ryan J Sullivan Research Topics

Disease

106	Melanoma (Melanoma, Malignant) 11/2022 - 05/2009
84	Neoplasms (Cancer) 11/2022 - 05/2009
13	Neoplasm Metastasis (Metastasis) 04/2022 - 10/2013
13	Disease Progression 11/2021 - 11/2012
12	Brain Neoplasms (Brain Tumor) 01/2022 - 05/2015
8	Myocarditis (Carditis) 01/2021 - 01/2018
6	Cardiogenic Shock 01/2021 - 01/2016
6	Colitis 01/2020 - 01/2016
5	Heart Block 01/2021 - 01/2018
4	Acute Kidney Injury (Acute Renal Failure) 01/2022 - 12/2019
4	Inflammation (Inflammations) 01/2021 - 11/2019
4	Uveal melanoma 01/2021 - 10/2013
4	Heart Arrest (Cardiac Arrest) 01/2021 - 01/2018
4	Kaposi Sarcoma (Kaposi's Sarcoma) 12/2010 - 06/2008
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2022 - 09/2016
3	Fever (Fevers) 01/2022 - 07/2008
3	Meningeal Carcinomatosis 10/2021 - 01/2020
3	COVID-19 01/2021 - 01/2020
3	Cardiovascular Diseases (Cardiovascular Disease) 11/2020 - 01/2018
2	Anaplastic Thyroid Carcinoma 04/2022 - 01/2018
2	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 11/2020
2	Interstitial Nephritis (Tubulointerstitial Nephritis) 01/2022 - 10/2020
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2021 - 07/2021
2	Histiocytic Sarcoma 10/2021 - 01/2020
2	Wounds and Injuries (Trauma) 07/2021 - 07/2008
2	Exanthema (Rash) 01/2021 - 01/2020
2	Breast Neoplasms (Breast Cancer) 01/2020 - 01/2019
2	Hypophysitis 09/2019 - 01/2018
2	Infections 12/2010 - 01/2009
2	Carcinogenesis 09/2009 - 04/2007
1	Colorectal Neoplasms (Colorectal Cancer) 04/2022
1	Chills 01/2022
1	Hypertension (High Blood Pressure) 01/2022
1	Adenocarcinoma 12/2021
1	Pancreatic Neoplasms (Pancreatic Cancer) 12/2021

Drug/Important Bio-Agent (IBA)

57	Immune Checkpoint InhibitorsIBA 11/2022 - 03/2013
18	IpilimumabIBA 10/2021 - 11/2012
17	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021 - 03/2013
12	trametinibIBA 01/2022 - 03/2013
12	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2014
11	Pharmaceutical PreparationsIBA 11/2022 - 12/2010
11	pembrolizumabIBA 06/2022 - 10/2013
11	dabrafenibIBA 04/2022 - 03/2013
10	AntibodiesIBA 01/2022 - 10/2013
9	Proteins (Proteins, Gene)FDA Link 11/2021 - 10/2013
9	Interleukin-2 (IL2)IBA 06/2021 - 01/2012
8	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 11/2022 - 07/2008
8	LigandsIBA 01/2021 - 03/2013
8	Biomarkers (Surrogate Marker)IBA 11/2020 - 01/2012
7	Phosphotransferases (Kinase)IBA 04/2022 - 01/2014
7	AntigensIBA 01/2022 - 03/2013
7	NivolumabIBA 10/2021 - 10/2013
6	VemurafenibIBA 01/2019 - 03/2013
5	CytokinesIBA 04/2022 - 04/2010
5	Monoclonal AntibodiesIBA 11/2021 - 06/2008
5	omega-Chloroacetophenone (Mace)IBA 01/2021 - 01/2018
5	SteroidsIBA 01/2021 - 01/2018
3	binimetinibIBA 06/2022 - 05/2020
3	encorafenibIBA 06/2022 - 05/2020
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 04/2022 - 10/2013
3	VaccinesIBA 04/2022 - 01/2018
3	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 01/2020
3	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 10/2021
3	GlucocorticoidsIBA 11/2021 - 01/2018
3	CTLA-4 AntigenIBA 02/2019 - 01/2017
2	CohesinsIBA 01/2022 - 01/2016
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021 - 12/2020
2	AntioxidantsIBA 01/2021 - 09/2009
2	Cell-Free Nucleic AcidsIBA 01/2021 - 11/2014
2	Small Interfering RNA (siRNA)IBA 11/2020 - 12/2015
2	Anti-Bacterial Agents (Antibiotics)IBA 10/2020 - 07/2008
2	Oxidoreductases (Dehydrogenase)IBA 01/2018 - 10/2007
2	ulixertinibIBA 01/2018 - 01/2018
2	Tyrosine Kinase InhibitorsIBA 09/2016 - 05/2015
1	2- (5- (3- chlorophenyl)- 6- (4- chlorophenyl)- 1- (1- (isopropylsulfonyl)- 3- methylbutan- 2- yl)- 3- methyl- 2- oxopiperidin- 3- yl)acetic acidIBA 10/2022
1	AlbuminsIBA 04/2022
1	Peptides (Polypeptides)IBA 04/2022
1	gamma Subunit Interferon-Stimulated Gene Factor 3 (Interferon Stimulated Gene Factor 3, gamma Subunit)IBA 01/2022
1	InterferonsIBA 01/2022
1	Ad26COVS1IBA 01/2022
1	2019-nCoV Vaccine mRNA-1273IBA 01/2022
1	EnzymesIBA 01/2022
1	BNT162 VaccineIBA 01/2022
1	COVID-19 VaccinesIBA 01/2022
1	Immunoglobulin A (IgA)IBA 01/2022
1	Histones (Histone)IBA 01/2022
1	cabozantinibIBA 01/2022
1	Lysine (L-Lysine)FDA Link 01/2022
1	Vaccine AdjuvantsIBA 12/2021
1	Toll-Like Receptor 9IBA 12/2021
1	Angiopoietin-2IBA 11/2021
1	tremelimumabIBA 11/2021
1	MEDI3617IBA 11/2021

Therapy/Procedure

89	Therapeutics 11/2022 - 01/2009
33	Immunotherapy 06/2022 - 03/2013
5	Radiotherapy 07/2021 - 08/2015
4	Drug Therapy (Chemotherapy) 01/2021 - 08/2015
3	Aftercare (After-Treatment) 01/2020 - 01/2016
3	Molecular Targeted Therapy 10/2013 - 05/2009
1	Cell- and Tissue-Based Therapy (Cell Therapy) 04/2022